This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Vyant Bio, Inc. Estimates Liquidation Payments to its Shareholders CI
Vyant Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Vyant Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
AxoSim, Inc. entered into an agreement to acquire microBrain?-associated assets from Vyant Bio, Inc. for $3.5 million. CI
Vyant Bio, Inc.(NasdaqCM:VYNT) dropped from S&P TMI Index CI
Vyant Bio, Inc.(OTCPK:VYNT) dropped from NASDAQ Composite Index CI
Top Midday Decliners MT
Vyant Bio to Voluntarily Delist From Nasdaq, Deregister From SEC; Shares Slide After Hours MT
Vyant Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Vyant Bio, Inc. Auditor Raises 'Going Concern' Doubt CI
HC Wainwright Downgrades Vyant Bio to Neutral From Buy MT
Vyant Bio CEO to Step Down, Successor Named; Cuts Staff as Strategic Review Process Gets Underway MT
Vyant Bio, Inc. Announces Executive Changes CI
Vyant Bio, Inc. Announces CEO Changes CI
Strong Labor Data in Spotlight After Hawkish Fed Minutes, US Equity Futures Turned Lower Ahead of Opening Bell MT
Top Premarket Gainers MT
Vyant Bio Taps LifeSci Capital to Assist in Review of Strategic Options MT
Vyant Bio Engages LifeSci Capital to Explore Strategic Alternatives CI
Top Premarket Decliners MT
Vyant Bio, Inc. Terminates the Employment Contract of Ralf Brandt, Ph.D. Effective December 31, 2022 CI
Transcript : Vyant Bio, Inc., Nine Months 2022 Earnings Call, Nov 16, 2022
Earnings Flash (VYNT) VYANT BIO Reports Q3 Revenue $152,000 MT
Vyant Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Vyant Bio, Inc. to Participate at Neuroscience 2022, the 52nd Annual Gathering of the Society for Neuroscience, on November 12-16, 2022 CI
Reaction Biology Corporation acquired vivoPharm, LLC from Vyant Bio, Inc. for approximately $6 million. CI
Chart Vyant Bio, Inc.
More charts
Vyant Bio, Inc. has no continuing operating activities other than the winddown and closure of its business. The Company is seeking to obtain its shareholders’ approval for the voluntary liquidation and dissolution of the Company, pursuant to a plan of liquidation and dissolution.
More about the company
  1. Stock Market
  2. Equities
  3. VYNT Stock
  4. News Vyant Bio, Inc.
  5. Vyant Bio CEO to Step Down, Successor Named; Cuts Staff as Strategic Review Process Gets Underway
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW